Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...

Alnylam’s Onpattro is a treatment for hereditary transthyretin-medicated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy. The rare and life-threatening disease is caused by ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported results. Among these, Bristol Myers reported better-than-expected ...

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post to the agency’s website. Published first on ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Alnylam Pharmaceuticals (ALNY) reports results for the quarter ended December 2024. While this widely-known ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...